A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sasaki, Takaaki, Koivunen, Jussi, Ogino, Atsuko, Yanagita, Masahiko, Nikiforow, Sarah, Zheng, Wei, Lathan, Christopher, Marcoux, J. Paul, Du, Jinyan, Okuda, Katsuhiro, Capelletti, Marzia, Shimamura, Takeshi, Ercan, Dalia, Stumpfova, Magda, Xiao, Yun, Weremowicz, Stanislawa, Butaney, Mohit, Heon, Stephanie, Wilner, Keith, Christensen, James G., Eck, Michel J., Wong, Kwok-Kin, Lindeman, Neal, Gray, Nathanael S., Rodig, Scott J., Jänne, Pasi A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278914/
https://ncbi.nlm.nih.gov/pubmed/21791641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-1340
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados